Patient demographics, clinical information and initial imaging data
| Variable | All patients (n=110) |
|---|---|
| Age, years, mean±SD | 61.5±17.0 |
| Male, n (%) | 60 (55.6) |
| Caucasian, n (%) | 95 (86.4) |
| Admission NIHSS, median (IQR) | 12 (7–19) |
| Follow-up mRS, median (IQR) | 3 (1–4) |
| Time to follow-up mRS from stroke, days, mean±SD | 96±51 |
| Hypertension, n (%) | 60 (54.6) |
| Hyperlipidaemia, n (%) | 41 (37.3) |
| Atrial fibrillation, n (%) | 33 (30.0) |
| Diabetes mellitus, n (%) | 23 (20.9) |
| Congestive heart failure, n (%) | 14 (12.7) |
| Current cigarette smoking, n (%) | 24 (21.8) |
| Admission glucose level, mg/dL, mean±SD | 127.1±40.2 |
| Collateral score (1–4), median (IQR) | 3 (2–4) |
| Lesion volume, mL, mean±SD | 43.8±40.6 |
| Hypoperfused volume, mL, mean±SD | 75.9±56.9 |
| Mismatch volume, mL, mean±SD | 36.8±31.1 |
| tPA administered, n (%) | 55 (50.0) |
| Endovascular therapy, n (%) | 44 (40.0) |
| Symptomatic intracerebral haemorrhage, n (%) | 13 (11.8) |
| Proximal vessel occlusion, n (%) | 58 (52.7) |
| SBP SD, 0–120 hours, mean±SD | 14.4±4.8 |
| SBP CV, 0–120 hours, mean±SD | 11.1±3.7 |
| SBP SV, 0–120 hours, mean±SD | 14.1±4.5 |
| SBP mean, 0–120 hours, mean±SD | 131.0±16.7 |
CV, coefficient of variation; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; SBP, systolic blood pressure; SV, successive variation; tPA, tissue plasminogen activator.